ZyVersa Therapeutics (NASDAQ:ZVSA) Stock Price Up 7.5%

Shares of ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) traded up 7.5% during mid-day trading on Thursday . The stock traded as high as $0.64 and last traded at $0.63. 422,022 shares were traded during mid-day trading, a decline of 82% from the average session volume of 2,335,399 shares. The stock had previously closed at $0.58.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and issued a $12.00 target price on shares of ZyVersa Therapeutics in a report on Tuesday, March 26th.

ZyVersa Therapeutics Stock Up 7.5 %

The firm’s fifty day moving average is $0.76 and its 200 day moving average is $1.66.

Institutional Investors Weigh In On ZyVersa Therapeutics

An institutional investor recently bought a new position in ZyVersa Therapeutics stock. Walleye Capital LLC acquired a new position in shares of ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 980,568 shares of the company’s stock, valued at approximately $128,000. Walleye Capital LLC owned about 3.17% of ZyVersa Therapeutics at the end of the most recent quarter. Institutional investors own 3.91% of the company’s stock.

ZyVersa Therapeutics Company Profile

ZyVersa Therapeutics, Inc, a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company engages in the development of VAR 200, a cholesterol efflux mediator, which is in Phase 2a clinical trial to the treatment of multiple renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic nephropathy; and IC 100, a monoclonal antibody inflammasome ASC inhibitor that is in preclinical stage for treatment of multitude of inflammatory diseases.